BioSpace News Archive

OcuTerra Therapeutics, Inc. today announced full enrollment in the company’s Phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial evaluating topically delivered OTT166 eye drops in adult patients with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) or mild proliferative diabetic retinopathy (PDR) with minimal vision loss.

Aptevo Therapeutics Inc. today announced that its bispecific AML drug candidate APVO436, in combination with emerging standard of care venetoclax and azacitidine, achieved positive duration of remission results in its Phase 1b dose escalation trial.

ENB Therapeutics, Inc. today announced that the company has completed enrollment of its international Phase 1 ENBOLDEN-101 trial investigating the safety and efficacy of lead product ENB-003 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

Annovis Bio, Inc. (NYSE: ANVS ), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), presented three posters at the Alzheimer’s Association International Conference (AAIC) 2023 annual meeting held in Amsterdam, Netherlands, from July 16-20.

BioCorRx Inc. today announced the submission of a fast track application to the U.S. Food and Drug Administration (“FDA”) for BICX104, an implantable biodegradable naltrexone pellet for the treatment of opioid use disorder (OUD).

Shockwave Medical, Inc. will report financial results for the second quarter 2023 after market close on Monday, August 7, 2023.

Baird Medical Investment Holdings Limited announced today that the Company’s independently developed and produced disposable MWA needle for the treatment of benign thyroid nodules received approval from China’s National Medical Products Administration (the “NMPA”) on July 13, 2023.

Verismo Therapeutics today announced it has raised $17M in a second pre-Series A financing round.

DiaMedica Therapeutics Inc. today announced the company will be attending the 2023 AAN Summer Conference on July 28-29, at the Minneapolis Hyatt Regency.

The Parkinson’s Foundation has announced an investment of $2.8 million in 30 grants to accelerate cutting-edge Parkinson’s disease research.